Regor Therapeutics scores $90m Series B

Regor Therapeutics, a clinical-stage biotechnology company focused on treating cancer, immune disorders and metabolic diseases, has closed $90 million in Series B financing.

Regor Therapeutics, a clinical-stage biotechnology company focused on treating cancer, immune disorders and metabolic diseases, has closed $90 million in Series B financing. Lilly Asia Ventures led the round with participation from other investors that included Loyal Valley Capital, Lanting Capital, TF Capital and Vertex Ventures China.

Source: Press Release